"MRS is a proven leader in providing access to breast health information. The ability to display Volpara results on the MRS workstation is another important milestone in widespread access to objective breast density values," said Dr. Ralph Highnam.
Wellington, New Zealand (PRWEB) June 07, 2012
Matakina International Limited of Wellington, New Zealand, and Mammography Reporting System, Inc. (MRS) of Seattle, Washington, today announced that the companies have signed an agreement that allows MRS to provide users of the MRS7 Reporting System with the ability to utilize the Volpara® breast density software scores in an updated User Interface. This agreement also grants MRS the rights to distribute Volpara® software.
The Volpara® breast density software is FDA-cleared product that offers radiologists a reliable and cost-effective tool to automatically generate objective volumetric breast tissue density values from digital screening mammograms. Volpara® automatically generates objective, automatic measurement of volumetric breast density values under the Volpara Density Grade (VDG®) – a refined grading system which correlates with the American College of Radiology BI-RADS® Density Grading Classifications. Integrations of Volpara® with other digital mammography and CAD systems are also underway.
“The objective measurement of breast density clearly offers important clinical information to improve the early detection of breast cancer, but the technology cannot be used effectively unless it is easily integrated into routine diagnostic workflow,” said Dr. Ralph Highnam, CEO, Matakina International, Ltd. “MRS is a proven leader in providing access to critical breast health information. The ability to display Volpara results on the MRS mammography workstation is another important milestone in widespread access to objective breast density values.”
Breast tissue density has been linked to an increased risk of breast cancer. Several large studies have confirmed that as tissue density increases, the accuracy of lesion detection through mammography decreases. Thirty-five percent of breast cancer goes undetected by mammography in women with dense breasts, as density masks the appearance of tumors (Boyd et al 2007, NEJM). Since both dense breast tissue and cancer appear white on a mammogram, finding cancers can be analogous to looking for a snowball in a snowstorm.
“We are pleased to establish a partnership with Matakina® to make Volpara® breast density software available to thousands of facilities that use MRS reporting and tracking systems,” said Mark Morris, CEO of MRS. “Adding Volpara® scores directly into the MRS7 Reporting System supports our mission of providing timely, relevant information that incorporates directly into the radiologist reporting workflow. Our customers have found that, providing radiologists with concurrent access to clinically relevant diagnostic information helps improve the overall quality of patient care while achieving time and cost savings for the radiologist.”
The MRS7 Reporting System is the newest standard for breast imaging tracking and reporting solutions. MRS7 Reporting helps promote efficiency and effectiveness in the radiologist’s workflow by providing a simple, user-friendly interface that combines functionality with security. MRS supports optimal patient care by providing features such as automated patient lay letters, high-risk modeling, and problem-case tracking. The addition of the Volpara® breast density software is an example of how MRS is constantly innovating and improving its products in order to better service the needs of customers and their facilities.
About Mammography Reporting System (MRS)
Mammography Reporting System (MRS) is the most widely used tracking & reporting system in the world for all breast-related procedures, including mammography, MRI, and Ultrasound. Their systems have been tracking patients, collecting data, and generating reports for nearly two decades. MRS’s success is based largely on an unparalleled patient communication package, accurate calculation of statistical reports, and consistently listening to our users. For more information, visit http://www.mrsys.com or call 800-253-4827.
Founded to enable radiologists to give women the most accurate information possible regarding their breast health, Matakina International, Limited is the wholly owned sales and marketing arm of Matakina Technology Limited of New Zealand. Volpara’s founders and Board of Directors includes John Hood, PhD, former Vice Chancellor of the University of Oxford, UK, Ralph Highnam, PhD, former CEO of Mirada Solutions, one of the University of Oxford’s most successful spin-outs of recent times and co-author of the seminal book Mammographic Image Analysis; and Professor Sir Michael Brady, a serial entrepreneur who recently retired from the University of Oxford where he was Professor of Information Technology for 25 years.
# # #
Chris K. Joseph